Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340

Benzinga · 1d ago
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $320 to $340.